Profile: Seattle Genetics Inc (SGEN.O)
9 Dec 2016
Seattle Genetics, Inc., incorporated on July 15, 1997, is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. It also has multiple preclinical and research-stage programs that employ its technologies.
The Company's ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). ADCETRIS employs a linker system that is designed to be stable in the bloodstream and to release MMAE upon internalization into CD30-positive cells. ADCETRIS has received marketing authorization in relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) by regulatory authorities in over 60 countries. ADCETRIS for intravenous injection has received approval for three indications, which include regular approval for the treatment of patients with classical Hodgkin lymphoma after failure of auto-hematopoietic stem cell transplantation (HSCT) or after failure of approximately two prior multi-agent chemotherapy regimens in patients; regular approval for the treatment of classical Hodgkin's lymphoma (HL) patients at high risk of relapse or progression as post-auto-HSCT consolidation, and accelerated approval for the treatment of patients with sALCL after failure of one prior multi-agent chemotherapy regimen.
SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody linked to a potent pyrrolobenzodiazepines (PBD) dimer using its ADC technology, and is a product candidate for the treatment of acute myeloid leukemia (AML). SGN-CD33A targets CD33, a protein that is expressed on most AML cells. The Company is conducting Phase I/II clinical trial of SGN-CD33A in patients with relapsed or refractory AML. The Phase I/II is an open-label, multi-center clinical trial.
SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody linked to a potent auristatin compound using its ADC technology, and is a product candidate for the treatment of hematologic malignancies. CD19 is a B-cell antigen that is expressed in non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia (ALL). The Company is focused on initiation of a randomized Phase II clinical trial of SGN-CD19A in combination with the second-line salvage regimen of rituximab, ifosfamide, carboplatin and etoposide (RICE), for patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL).
SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody linked to a potent auristatin compound using its ADC technology, and is a product candidate for the treatment of LIV-1-positive metastatic breast cancer. The Company is conducting a Phase I, open-label, dose-escalation clinical trial to evaluate the safety and antitumor activity of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer.
SGN-CD70A is an ADC composed of an anti-CD70 monoclonal antibody with engineered cysteines (EC-mAb) linked to a potent PBD dimer using its ADC technology, and is a product candidate for the treatment of CD70-positive renal cell carcinoma and non-Hodgkin lymphoma. This product candidate is being evaluated in a Phase I, open-label, multi-center, dose-escalation clinical trial evaluating SGN-CD70A for CD70-positive renal cell carcinoma.
SEA-CD40 utilizes its SEA technology to produce a non-fucosylated antibody targeting CD40. The Company is conducting a Phase I, open label, multi center and dose escalation trial of SEA-CD40 in patients with advanced solid tumors.
ASG-22ME is an ADC composed of an anti-Nectin-4 monoclonal antibody linked to a potent auristatin compound using its ADC technology. Nectin-4 is a target expressed in multiple cancers, including bladder, breast, lung and pancreatic cancers. The Company is developing ASG-22ME as a potential treatment of solid tumors under its co-development collaboration with Agensys. The Company has completed the Phase I clinical trial of ASG-22ME.
ASG-15ME is an ADC composed of an anti-SLITRK6 monoclonal antibody linked to a potent auristatin compound using its ADC technology. SLITRK6 is a target expressed in bladder and lung cancer. It is developing ASG-15ME as a product candidate for the treatment of bladder cancer under its co-development collaboration with Agensys. The Company is conducting Phase I clinical trial of ASG-15ME for the treatment of bladder cancer.
The Company competes with AstraZeneca, ImmunoGen, Pfizer, Inc., Sanofi-Aventis, Roche Group, Novartis, Lilly, Bristol-Myers Squibb Corporation, Amgen, Xencor, AbbVie Biotechnology Ltd., Bayer Pharma AG, Celgene, Eisai, GlaxoSmithKline LLC, Gilead, Infinity, Merck, Spectrum Pharmaceuticals, Takeda Pharmaceutical Company Limited, Teva, Affimed, Karyopharm, MEI Pharma and Agios.
Seattle Genetics Inc
21823 30th Dr SE
BOTHELL WA 98021-3907
Company Web Links
- BRIEF-Seattle Genetics receives FDA breakthrough therapy designation for Adcetris
- BRIEF-Seattle Genetics, Agensys highlights promising Enfortumab Vedotin, ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress
- BRIEF-Seattle Genetics starts phase 1 trial of SGN-CD123A for patients with relapsed leukemia
- Pfizer boosts cancer drug roster with $14 billion Medivation deal |
- UPDATE 5-Pfizer boosts cancer drug roster with $14 bln Medivation deal